IMUX · Immunic, Inc.

Immunic, Inc. has executed a significant leadership transition in its clinical development organization, appointing Michael A. Panzara, M.D., M.P.H. as Chief Medical Officer to succeed co-founder Andreas Muehler, M.D., M.B.A. Dr. Panzara brings deep expertise in neurology drug development, having previously served as Chief Medical Officer at Neurvati Neurosciences and Wave Life Sciences, and holding leadership roles at Sanofi Genzyme and Biogen where he oversaw the development and global regulatory approvals of multiple blockbuster multiple sclerosis (MS) therapies including LEMTRADA, AUBAGIO, and TYSABRI. This experience is directly relevant to Immunic's lead asset, vidofludimus calcium, which is currently in pivotal Phase 3 trials for relapsing MS with top-line data expected by the end of 2026.

Dr. Panzara's compensation package includes a $600,000 base salary, a target bonus of 50%, a $125,000 signing bonus, and an inducement equity grant of 300,000 stock options. The appointment was structured as an inducement award under NASDAQ Listing Rule 5635(c)(4). Concurrently, the departure of Dr. Muehler was structured to ensure continuity; he will serve as a Senior Medical Officer through April 30, 2026, and then as a consultant for ten months. The separation agreement provides Dr. Muehler with twelve months of salary continuation, a pro-rated 2026 bonus, and full acceleration of his outstanding equity awards, indicating an amicable transition designed to retain his institutional knowledge during a critical period for the company's lead program.